All primary antibodies were conjugated with red and green fluorophores using a commercial antibody labeling technology (Zenon; Invitrogen), according to the manufacturer’s instructions. hfRPE cells were either placed on ice and fixed for 10 minutes in ice-cold methanol or fixed in 4% formaldehyde for 30 minutes at room temperature and permeabilized with 0.1% Triton-X100. After treatment with a solution containing a signal enhancer (Image-IT FX; Invitrogen) for 30 minutes at room temperature, the cells were incubated with the following fluorophore labeled primary antibodies: mouse anti-JAM-C (BD Biosciences, San Jose, CA), rabbit anti-desmoplakin (AbD Serotec, Raleigh, NC), mouse anti-E-cadherin (EMD Biosciences-Calbiochem, San Diego, CA), mouse anti-ZO-1 (Zymed-Invitrogen), and mouse anti-occludin-FITC (Zymed-Invitrogen). After antibody incubation, the cells were treated with 4% paraformaldehyde-PBS (PFA) for an additional 15 minutes at room temperature, mounted on glass slides (Prolong Gold; Invitrogen), and imaged with a fluorescence microscope (Axioplan 2 with Axiovision 3.4 software using ApoTome; Carl Zeiss Meditec, Inc., Dublin, CA, or SP2 confocal microscope; Leica, Bannockburn, IL). To confirm the localization of JAM-C in the apical processes of human fetal RPE cells, we used the following three antibodies: (1) Gi11/human epitope (BD Pharmingen, San Diego, CA); (2) AF1213/ mouse epitope (R&D Systems, Minneapolis, MN; and (3) PACA4 (generous gift of Tony Liang of Raven Biotechnologies, South San Francisco, CA). To maximize resolution in our localization studies of JAM-C, short-wave length–emitting fluorophores were used. The anti-JAM-C antibody was conjugated with a blue fluorochrome (350 nm), whereas the anti-ZO-1, anti-occludin, anti-E-cadherin, and anti-desmoplakin antibodies were conjugated with FITC (488 nm). The blue fluorophore data are presented in pseudocolor (red) instead of blue.